Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 256 to 270 of 434 results for cardiovascular disease

  1. Targeted-release budesonide for treating primary IgA nephropathy (TA1128)

    Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.

    Technology appraisal guidance
    Published
    4 February 2026
    View recommendations

    Sections for TA1128

  2. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  3. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  4. Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)

    Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.

    Technology appraisal guidance
    Published
    28 October 2009
    View recommendations

    Sections for TA183

  5. Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (CG67)

    This guidance has been updated and replaced by NICE guideline CG181.

    Withdrawn guideline

  6. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  7. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  8. Pulsed-field ablation for atrial fibrillation (HTG755)

    Evidence-based recommendations on pulsed-field ablation for atrial fibrillation. This involves using electric field energy to destroy heart cells that are transmitting abnormal electrical impulses.

    HealthTech guidance
    Published
    10 July 2025
    View recommendations

    Sections for HTG755

  9. Interventional procedures advisory committee members

    Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.

  10. Interventional procedures advisory committee members

    Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.

  11. Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (TA1017)

    Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults

    Technology appraisal guidance
    Published
    20 November 2024
    View recommendations

    Sections for TA1017

  12. Cardiovascular disease prevention: statins for people newly diagnosed with hypertension or T2DM (IND162)

    This indicator has been updated and replaced by NICE indicator 287.

    Withdrawn indicator

  13. Everolimus for preventing organ rejection in liver transplantation (TA348)

    Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in adults having a liver transplant.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA348

  14. Stage 4: treatment, assessment and monitoring

    In virtual wards, people can receive virtual and technology-assisted treatment, assessment, and monitoring.

  15. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)

    Evidence-based recommendations on tocilizumab (RoActemra), for treating systemic juvenile idiopathic arthritis in people aged 2 and over.

    Technology appraisal guidance
    Published
    14 December 2011
    View recommendations

    Sections for TA238